Among diverse oncogenic factors, mutations of the FMS-related receptor tyrosine kinase 3 (FLT3) are expressed in ~35% of AML patients (FLT3-mut AML), who respond poorly to salvage chemotherapies [3]. The gene discussed is FLT3; the disease is acute myeloid leukemia.